Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab with PD-L1 PET imaging in resectable oral cancer
2018-002643-28Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Oral Mucosal Carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: PET Imaging. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2018-002643-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002643-28.